Advancing Trustworthy AI in Life Sciences
A global, multi-stakeholder initiative uniting regulators, industry, academia, and technology innovators to tackle the practical challenges of AI in drug development.
About the Consortium
The DIA Artificial Intelligence Consortium develops actionable frameworks, tools, and guidance so AI can be implemented in drug development safely, effectively, and responsibly — bringing together regulators, industry, academia, and technology innovators around a shared set of standards.
View Consortium Charter & Terms of Reference
Explore by Phase
The consortium's work is organized into phases. Phase 1 is complete; Phase 2 is the active, current phase. Select a phase below to see working groups, leadership, timeline, and deliverables.
Working groups, timeline, leadership, and deliverables from the consortium's first phase — 25 organizations, 49 members.
View the Phase 1 ArchiveExecutive committee, current goals, meeting schedule, and deliverables in progress — 36 organizations and growing.
See What's Happening NowWhat We've Accomplished
In Phase 1, the consortium:
Defined a structured AI use case definition and classification framework
Created practical AI/ML model validation guidance to evaluate quality, reliability, and fitness-for-purpose
Harmonized regulatory terminology and frameworks to support cross-jurisdictional alignment
Why It Matters
This work benefits the life sciences community by establishing shared frameworks and standards, ensuring AI can be implemented safely, effectively, and responsibly.
Supporting regulatory and organizational decision-making grounded in validated evidence and structured AI classification frameworks.
Promoting harmonized global practices for AI in life sciences across regulators, regions, and disciplines to reduce friction and improve alignment.
Driving collaboration among regulators, industry, and academia to advance innovation and ultimately improve scientific rigor and patient outcomes.
Regulators, Industry, and Academia — Together
36 organizations across regulatory agencies, biopharma, health systems, and academic institutions currently participate in Phase 2, building on the 25 organizations that shaped Phase 1.
Benefits of Membership
Participation is open to partner organizations dedicated to advancing trustworthy AI in the life sciences.
Related Initiatives
Browse other active consortia and research projects within the DIA Research portfolio.
Advancing trustworthy AI frameworks across drug discovery, development, and regulatory domains.
Learn More →
Cross-sector work to address shared challenges and accelerate progress in obesity drug development.
Learn More →
Advisory-guided research with defined deliverables and clear impact metrics for drug tolerability assessment.
Learn More →Consortium in Action
Moments from AI Consortium sessions and meetings at the DIA Global Annual Meeting.
